| Phase 12 trials |
|
Phase 1
|
NCT06115902 |
Nov 2023 → Feb 2025 |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05735496 |
Mar 2023 → Jul 2025 overdue |
cancer of unknown primary site |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT07512583 |
May 2026 → Mar 2028 expected |
neoplasm |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06431490 |
Jul 2024 → May 2027 expected |
biliary tract cancer |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 29 trials |
|
Phase 2
|
NCT07419880 |
Jan 2026 → Jan 2027 expected |
triple-negative breast carcinoma |
Fudan University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07136974 |
Sep 2025 → Aug 2028 expected |
HER2 positive breast carcinoma |
Henan Cancer Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06798207 |
Mar 2025 → May 2026 overdue |
female reproductive system neoplasm |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06767800 |
Nov 2024 → Sep 2026 expected |
gastroesophageal adenocarcinoma |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06452706 |
Nov 2024 → Jun 2026 overdue |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06496490 |
Aug 2024 → Jun 2026 overdue |
non-small cell lung carcinoma |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06198751 |
Feb 2024 → May 2025 overdue |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05749588 |
Mar 2023 → Dec 2027 expected |
triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05582499 |
Nov 2022 → Dec 2027 expected |
HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
| Phase 35 trials |
|
Phase 3
|
NCT07483684 |
Mar 2026 → Aug 2027 expected |
carcinoma |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07043725 |
Sep 2025 → Sep 2027 expected |
HER2 positive breast carcinoma |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07008976 |
Jul 2025 → Mar 2028 expected |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07003074 |
Jun 2025 → Jul 2029 expected |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06561607 |
Aug 2024 → Jan 2027 expected |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|